Tsukuba, Japan

Atsushi Kamada

This inventor holds 16 USPTO granted patents and 1 published patent application, plus 7 CIPO patents and 8 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Eisai R&d Management Co., Ltd., Eisai Company, Limited, Eisai R&D Management Co., Ltd.. Active years: 2001-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Atsushi Kamada. Retrieved from https://idiyas.com/inventor/atsushi-kamada-wb1kbr6p

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 16 

% Patents Active = 56.3


 

Average Co-Inventor Count = 7.7

ph-index = 7

Forward Citations = 246(Granted Patents)


Location History:

  • Ibaraki, JP (2001 - 2004)
  • Ushiku, JP (2007)
  • Tsukuba, JP (2009 - 2013)

Company Filing History:


Years Active: 2001-2026

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Monocyclic Pyridine
Selective Estrogen Receptor Modulator
Phenoxypyridine Derivatives
Indole Derivative
Water-Soluble Azole Prodrugs
Crystalline Form
2-Iminoimidazole Derivatives
Benzopiperidine Derivatives
Phthalazine Compounds
Erectile Dysfunction
Carbapenem Intermediates
Stereoselective Manufacturing
16 patents (USPTO):Explore Patents

Title: **Atsushi Kamada: A Pioneer in Antitumor Innovations**

Introduction

Atsushi Kamada, based in Tsukuba, Japan, is an accomplished inventor with a remarkable portfolio of 15 patents. His innovative contributions primarily focus on the development of pharmaceutical compounds that serve critical functions in cancer treatment.

Latest Patents

Among Atsushi Kamada's latest patents is a selective estrogen receptor modulator, which introduces a compound represented by a complex formula designed for therapeutic applications. This innovation includes elements such as a bivalent heterocyclic group and phenylene structures, demonstrating potential as an anti-tumor agent and an angiogenesis inhibitor. His work also encompasses phenoxypyridine derivative salts and crystals that exhibit HGFR inhibitory activity, showcasing exceptional properties including solubility and safety, further establishing their utility in combating various types of tumors.

Career Highlights

Atsushi's career has been enriched by his tenure with renowned institutions like Eisai R&D Management Co., Ltd. and Eisai Company, Limited. His role in these companies has allowed him to advance his research and translate innovative concepts into patentable technologies that address pressing medical needs.

Collaborations

Throughout his career, Atsushi has collaborated with notable colleagues, including Fumihiro Ozaki and Kazumasa Nara. These partnerships have facilitated a dynamic exchange of ideas and expertise, enhancing the quality and depth of his research.

Conclusion

Atsushi Kamada stands as a pivotal figure in the realm of pharmaceutical innovation. With his significant contributions to antitumor compounds and ongoing collaborations, he continues to impact the medical field profoundly, fostering advancements that hold promise for improved cancer therapies.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…